Thomas J. Guzzo¹, Alexander Kutikov², Daniel J. Canter², John E. Tomaszewski³, Laurie Magerfleish², Keith VanArsdalen², Alan J. Wein², S. Bruce Malkowicz²

Canadian Journal of Urology, Vol.15, No.4, pp. 4174-4179, 2008

Abstract Objectives: The natural history of high grade prostatic intraepithelial neoplasia (HGPIN) is incompletely understood limiting evidence based recommendations regarding screening and repeat biopsy intervals. Our objective was to evaluate the natural history of HGPIN to better assess the time frame to disease progression and the pathological findings at the time of progression to cancer.
Methods and materials: We retrospectively reviewed 74 consecutive patients with an initial diagnosis of HGPIN. The number and timing of all biopsies leading to the diagnosis of cancer were assessed. Clinical and pathological features of those patients with eventual disease progression were evaluated.
Results:… More >

Gabriel P. Haas

Canadian Journal of Urology, Vol.15, No.4, pp. 4179-4179, 2008

Abstract This article has no abstract. More >

Kaili Mao¹, Cécile Badoual², Philippe Camparo³, Nicolas Barry Delongchamps¹, Annick Vieillefond⁴, Anh-Tuan Dinh-Xuan⁵, Michaël Peyromaure¹

Canadian Journal of Urology, Vol.15, No.5, pp. 4257-4262, 2008

Abstract Objectives: To study the prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor VEGFR-1 in localized prostate cancer.
Methods: One hundred patients undergoing radical prostatectomy (RP) for clinically localized prostate cancer were prospectively included. Plasma levels of VEGF-A were measured preoperatively. After intervention, tissue microarrays were built from the RP specimens. VEGF-A and VEGFR-1 expressions in prostate cancer tissue were determined using immunochemistry. Then the associations between plasma levels of VEGF-A, VEGF-A and VEGFR-1 expressions in prostate cancer tissue, and the outcome of patients were analyzed.
Results: After a median follow-up of 22 months, 14 patients More >

Alvaro Morales

Canadian Journal of Urology, Vol.15, No.5, pp. 4256-4256, 2008

Abstract This article has no abstract. More >

Christopher J. DiBlasio¹, Jessica Hammett¹, John B. Malcolm¹, Beth A. Judge², Jamie H. Womack², Matthew C. Kincade¹, Mitchell L. Ogles¹, John M. Mancini¹, Anthony L. Patterson¹, Robert W. Wake¹, Ithaar H. Derweesh¹

Canadian Journal of Urology, Vol.15, No.5, pp. 4249-4256, 2008

Abstract Objective: Androgen deprivation therapy (ADT) remains a widely utilized modality for treatment of localized and advanced prostate cancer. While ADT-induced alterations in testosterone have demonstrated impacts on quality of life, the effects on mental health remain ill-defined. We investigated the prevalence of de novo psychiatric illness and predictive factors following ADT induction for prostate cancer.
Materials and methods: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between 1/1989-7/2005, excluding men receiving only neoadjuvant ADT. Variables included age, race, body mass index, prostate-specific antigen (PSA), Gleason sum, clinical stage, ADT type (medical/surgical) and schedule… More >

Daniel Taussky¹, Aihua Liu², Michal Abrahamowicz², Eve Léger-Bélanger¹, Jean-Paul Bahary¹, Marie-Claude Beauchemin¹, Thu Van Nguyen¹, David Donath¹, Fred Saad³

Canadian Journal of Urology, Vol.15, No.6, pp. 4415-4420, 2008

Abstract Objective: The present study aimed to analyze factors influencing treatment decisions in patients diagnosed with low risk prostate cancer who were referred to a brachytherapy clinic and had to choose from four treatment options: expectant management (watchful waiting), radical prostatectomy, external beam radiation therapy, and permanent seed brachytherapy.
Methods: We analyzed factors that influenced the treatment decisions of 110 consecutive patients with low risk prostate cancer who were referred to a brachytherapy clinic in a hospital in Montreal, Canada. These factors included patient age, marital status, and profession, as well as referral source (a urologist or a… More >

Eric A. Singer, Dragan J. Golijanin, Edward M. Messing

Canadian Journal of Urology, Vol.15, No.6, pp. 4381-4387, 2008

Abstract Androgen deprivation therapy (ADT) has been the cornerstone of treatment for advanced prostate cancer for over 65 years. Although there can be worrisome side effects, data will be presented that for men with metastatic prostate cancer, immediate ADT can reduce the likelihood of developing the rare but catastrophic sequellae of metastatic disease, although it is unlikely to prolong survival compared with waiting for symptoms before initiating ADT. Additionally, for patients with extremely high risk prostate cancer that is not distantly metastatic (e.g. have a life expectancy from prostate cancer less than 10 years with all… More >

Bilal Chughtai, Badar M. Mian

Canadian Journal of Urology, Vol.15, No.6, pp. 4375-4380, 2008

Abstract Advances in the early detection and treatment of prostate cancer have progressed far beyond our ability to identify patients with high risk prostate cancer. In general, designation of high risk prostate cancer implies the presence of disease that is likely become progressive or lethal if not managed aggressively. Without proper risk stratifi cation, there is a signifi cant likelihood of both overtreatments of men with low risk disease and undertreatment for men with high risk cancer. The major issues surrounding the clinical management of high risk prostate cancer revolve around the defi nition of high… More >

Shahrokh F. Shariat, Peter T. Scardino, Hans Lilja

Canadian Journal of Urology, Vol.15, No.6, pp. 4363-4374, 2008

Abstract The introduction of total prostate-specifi c antigen (tPSA) testing in serum has revolutionized the detection and management of men with prostate cancer. This review will highlight some of the exciting new developments in the fi eld of prostate cancer screening in general and from our SPORE research program at Memorial-Sloan Kettering Cancer Center. First, it is important to understand that the inherent variability of tPSA levels affects the interpretation of any single results. Total variation in tPSA includes both analytical (i.e., pre-analytical sample handling, laboratory processing, assay performance, and standardization) and biological variation (i.e., metabolism,… More >

Michael J. Manyak

Canadian Journal of Urology, Vol.14, Suppl.6, pp. 32-38, 2007

Abstract Rapid advances in imaging technology have whetted our collective appetites for practical clinical applications to assist the physician and patient in therapeutic decisions. Current limitations of imaging technology are being addressed by the convergence of technology in materials science, the computer industry, and biology which have led to improvements of diagnostic imaging. Refinements in image acquisition, fusion of images, and outcomes data now suggest use for image-guided therapy. Novel imaging agents and technologies appear to provide improved capabilities to detect malignant lymph nodes. Future applications of optical coherence tomography, electron paramagnetic resonance imaging, nanotechnology, and More >